Brand Companies Will “Lose Interest” In Generic Divisions, Watson Predicts
This article was originally published in The Pink Sheet Daily
Executive Summary
Watson expects history to repeat itself as brand name manufacturers experiment with in-house generic drug divisions
You may also be interested in...
J&J Going Generic? McNeil “Exploratory Project” May Pave The Way
“Patriot” division is appearing at trade shows in an “intelligence-gathering” capacity, McNeil says. An in-house generic operation would provide J&J with a greater share of profits than “authorized” generic deals.
J&J Going Generic? McNeil “Exploratory Project” May Pave The Way
“Patriot” division is appearing at trade shows in an “intelligence-gathering” capacity, McNeil says. An in-house generic operation would provide J&J with a greater share of profits than “authorized” generic deals.
Mylan's Legal Fight Against "Authorized" Generics May Shift To Antitrust Attack
Generic firm dismisses lawsuit against FDA seeking a preliminary injunction related to Watson's marketing of a Macrobid "authorized" generic. Dismissal comes shortly before a W.Va. federal judge was expected to rule on claims under the FD&C Act and Administrative Procedures Act. Mylan could revive its lawsuit through antitrust claims.